Anpac Bio Med Science Co. Ltd.
13F holders, Q2 2024 (June 30)3holders +2
2new positions
0sold out
$0.33avg. 13F price*
At the end of Q2 2024, 3 institutions reported holding Anpac Bio Med Science Co. Ltd. in their 13F filings, up 2 from Q1 2024. 2 opened new positions and 0 sold out. The largest holders were UBS Group AG ($14K), Two Sigma Securities, LLC ($6K) and Rhumbline Advisers ($2K).
- Company
- Anpac Bio Med Science Co. Ltd.
- Filed as
- FRESH2 GROUP LIMITED (Q2 2024)
- CUSIP
- 03635R206
- Latest filing quarter
- Q2 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $20K |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 58,692 shares bought, net +58,692 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| UBS Group AG | 0.00% | New | 40,623 | $14K |
| Two Sigma Securities, LLC | 0.00% | New | 18,069 | $6K |
| Rhumbline Advisers | 0.00% | No change | 6,678 | $2K |
"% of holder's portfolio" is ANPAC BIO MED SCIENCE CO LTD's weight in each manager's 13F, not the share of Anpac Bio Med Science Co. Ltd. the manager owns.